Business Description
Scopus BioPharma Inc
NAICS : 325412
SIC : 2834
ISIN : US8091711015
Description
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -18.98 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -45.5 | |||||
| 3-Year EPS without NRI Growth Rate | -45.1 | |||||
| 3-Year FCF Growth Rate | -39.4 | |||||
| 3-Year Book Growth Rate | -272.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.7 | |||||
| 9-Day RSI | 40.15 | |||||
| 14-Day RSI | 39.36 | |||||
| 6-1 Month Momentum % | -95.3 | |||||
| 12-1 Month Momentum % | -96.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.05 | |||||
| Quick Ratio | 0.05 | |||||
| Cash Ratio | 0.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.1 | |||||
| Shareholder Yield % | -2946.27 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -949.04 | |||||
| ROIC % | -9019.31 | |||||
| ROC (Joel Greenblatt) % | -389333.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.03 | |||||
| EV-to-EBITDA | 0.03 | |||||
| EV-to-FCF | 0.1 | |||||
| Earnings Yield (Greenblatt) % | 3333.33 | |||||
| FCF Yield % | -4541.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SCPS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scopus BioPharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.32 | ||
| Beta | 0.96 | ||
| Volatility % | 124.25 | ||
| 14-Day RSI | 39.36 | ||
| 14-Day ATR ($) | 0.000419 | ||
| 20-Day SMA ($) | 0.001695 | ||
| 12-1 Month Momentum % | -96.46 | ||
| 52-Week Range ($) | 0.0002 - 0.105 | ||
| Shares Outstanding (Mil) | 42.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scopus BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scopus BioPharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Scopus BioPharma Inc Frequently Asked Questions
What is Scopus BioPharma Inc(SCPS)'s stock price today?
The current price of SCPS is $0.00. The 52 week high of SCPS is $0.11 and 52 week low is $0.00.
When is next earnings date of Scopus BioPharma Inc(SCPS)?
The next earnings date of Scopus BioPharma Inc(SCPS) is 2024-05-10 Est..
Does Scopus BioPharma Inc(SCPS) pay dividends? If so, how much?
Scopus BioPharma Inc(SCPS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers